Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,711 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.
Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Hennigan ST, et al. Among authors: wilkinson s. JCO Precis Oncol. 2019;3:PO.19.00176. doi: 10.1200/PO.19.00176. Epub 2019 Sep 9. JCO Precis Oncol. 2019. PMID: 31528835 Free PMC article.
A case report of multiple primary prostate tumors with differential drug sensitivity.
Wilkinson S, Harmon SA, Terrigino NT, Karzai F, Pinto PA, Madan RA, VanderWeele DJ, Lake R, Atway R, Bright JR, Carrabba NV, Trostel SY, Lis RT, Chun G, Gulley JL, Merino MJ, Choyke PL, Ye H, Dahut WL, Turkbey B, Sowalsky AG. Wilkinson S, et al. Nat Commun. 2020 Feb 13;11(1):837. doi: 10.1038/s41467-020-14657-7. Nat Commun. 2020. PMID: 32054861 Free PMC article.
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.
Karzai F, Walker SM, Wilkinson S, Madan RA, Shih JH, Merino MJ, Harmon SA, VanderWeele DJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M, Couvillon A, Hankin A, Williams MN, Lis RT, Ye H, Choyke PL, Gulley JL, Sowalsky AG, Turkbey B, Pinto PA, Dahut WL. Karzai F, et al. Among authors: wilkinson s. Clin Cancer Res. 2021 Jan 15;27(2):429-437. doi: 10.1158/1078-0432.CCR-20-2344. Epub 2020 Oct 6. Clin Cancer Res. 2021. PMID: 33023952 Free PMC article. Clinical Trial.
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, Madan RA, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Wilkinson S, et al. Eur Urol. 2021 Dec;80(6):746-757. doi: 10.1016/j.eururo.2021.03.009. Epub 2021 Mar 27. Eur Urol. 2021. PMID: 33785256 Free PMC article.
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Sweeney CJ, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky AG, He HH, Freedman ML, Balk SP, Loda M, Labbé DP, Olson BM, Ellis L. Morel KL, et al. Among authors: wilkinson s. Nat Cancer. 2021 Apr;2(4):444-456. doi: 10.1038/s43018-021-00185-w. Epub 2021 Mar 22. Nat Cancer. 2021. PMID: 33899001 Free PMC article.
Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S, Ye H, Lis RT, Sowalsky AG. Wilkinson S, et al. Eur Urol. 2021 Sep;80(3):e83-e84. doi: 10.1016/j.eururo.2021.06.002. Epub 2021 Jun 18. Eur Urol. 2021. PMID: 34148711 No abstract available.
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. Calagua C, et al. Among authors: wilkinson s. Clin Cancer Res. 2021 Sep 1;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24. Clin Cancer Res. 2021. PMID: 34168052 Free PMC article.
1,711 results